GCOR Genencor International, (MM)

Genencor/NREL Team Wins R&D Top 100 Award for Work Enabling the Conversion of Biomass to Ethanol R&D Magazine's List of Most Technological Significant Products PALO ALTO, Calif., July 14 /PRNewswire-FirstCall/ -- Genencor International, Inc. (NASDAQ:GCOR), and a team from the U.S. Department of Energy's National Renewable Energy Laboratory (NREL) have been selected by R&D Magazine for its list of the Top 100 Technologically Significant Products for 2004. The organizations were cited for their progress toward an economical process for converting biomass to ethanol. The award is shared with Novozymes Biotech, Inc. According to NREL, the technology is expected to allow a wide range of biomass resources to be used to produce energy and chemicals. It is an important step toward realizing the potential of biorefineries -- in which plant and waste materials are used to produce an array of fuels and chemicals, analogous to an oil refinery today. Through this technology, the cost of converting cellulosic biomass into usable sugars can be reduced by more than 20 times per gallon of ethanol produced. "We're extremely pleased to receive this recognition and continue to work toward making biorefineries a reality," said Bill Dean, Genencor vice president of Development. The complete list of award winners will be revealed in the September issue of R&D Magazine. About Genencor Genencor International is a diversified biotechnology company that develops and delivers innovative products and services into the health care, agri-processing, industrial and consumer markets. Using an integrated set of technology platforms, Genencor's products deliver innovative and sustainable solutions to improve the quality of life. Genencor traces its history to 1982 and has grown to become a leading biotechnology company, with over $380 million in year 2003 annual revenues. Genencor has principal offices in Palo Alto, California; Rochester, New York; and Leiden, the Netherlands. This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These include statements concerning plans, objectives, goals, strategies, future events or performance and all other statements which are other than statements of historical fact, including without limitation, statements containing words such as "believes," "anticipates," "expects," "estimates," "projects," "will," "may," "might" and words of a similar nature. Such statements involve risks and uncertainties that could cause actual results to differ materially from those projected. Some important factors that could cause actual results to differ include dependence on the efforts of third parties; dependence on new and uncertain technology and its uncertain application to new business ventures; regulatory actions or delays, or uncertainties related to product development, testing or manufacturing; ability to form and maintain strategic alliances; dependence on certain intellectual property rights of both Genencor and third parties; and the competitive nature of Genencor's industry; risks of obsolescence of certain technology. These and other risk factors are more fully discussed in Genencor's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the United States Securities and Exchange Commission. The forward-looking statements contained in this release represent the judgment of Genencor as of the date of this press release. Genencor disclaims, however, any intent or obligation to update any forward-looking statements. DATASOURCE: Genencor International, Inc. CONTACT: Valerie Tucker of Genencor International, Inc., +1-650-846-7571 Web site: http://www.genencor.com/

Copyright